ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Health Canada Grants Priority Review to AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir
February 06, 2017AbbVie has submitted a New Drug Submission (NDS), and received priority review from Health Canada, for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of all major chronic hepatitis C viru
Pharma Sources Insight January 2025
